

**NATIONAL
MARROW
DONOR
PROGRAM®**

Entrusted to operate the C.W. Bill Young Cell Transplantation Program,
including Be The Match RegistrySM

November 05, 2009

Cdr. Elizabeth Montcalm-Smith
Office of Naval Research (ONR 342)
875 N. Randolph St.
Arlington, VA 22203-1995

Subject: Quarterly Performance/Technical Report of the National Marrow Donor Program®

Reference: Grant Award #N00014-08-1-1207 between the Office of Naval Research and the National Marrow Donor Program

Dear Cdr. Montcalm-Smith:

Enclosed is subject document which provides the performance activity for each statement of work task item of the above reference for the period of July 1, 2009 to September 30, 2009.

Should you have any questions as to the scientific content of the tasks and the performance activity of this progress report, you may contact our Chief Medical Officer – Dennis L Confer, MD directly at 612-362-3425.

With this submittal of the quarterly progress report, the National Marrow Donor Program has satisfied the reporting requirements of the above reference for quarterly documentation. Other such quarterly documentation has been previously submitted under separate cover.

Please direct any questions pertaining to the cooperative agreement to my attention (612-362-3403 or at cabler@nmdp.org).

Sincerely,



Carla Abler-Erickson, MA
Sr. Contracts Representative

Enclosure: Quarterly Report with SF298

C: D. Ivery – ACO (ONR-Chicago), letter and enclosure
Dr. Robert J. Hartzman, CAPT, MC, USN (Ret): letter and enclosure
Jennifer Ng, PhD – C.W. Bill Young Marrow Donor Recruitment and Research Program, letter and enclosure
J. Rike - DTIC (Ste 0944): letter and enclosure
NRL (Code 5227): letter and enclosure
Dennis Confer, MD, Chief Medical Officer, NMDP, letter only
Michelle Setterholm, NMDP letter only

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Service, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188) Washington, DC 20503.					
PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 05-11-09		2. REPORT TYPE Quarterly		3. DATES COVERED (From - To) Jul – Sep 2009	
4. TITLE AND SUBTITLE Quarterly Performance / Technical Report				5a. CONTRACT NUMBER N/A	
				5b. GRANT NUMBER N00014-08-1-1207	
				5c. PROGRAM ELEMENT NUMBER N/A	
6. AUTHOR(S) Setterholm, Michelle				5d. PROJECT NUMBER N/A	
				5e. TASK NUMBER Project 1, 2, 3, 4	
				5f. WORK UNIT NUMBER N/A	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) National Marrow Donor Program 3001 Broadway St., N.E., Ste. 500 Minneapolis, MN 55413				8. PERFORMING ORGANIZATION REPORT NUMBER N/A	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Office of Naval Research 875 N. Randolph St. Arlington, VA 22203				10. SPONSOR/MONITOR'S ACRONYM(S) ONR	
				11. SPONSORING/MONITORING AGENCY REPORT NUMBER N/A	
12. DISTRIBUTION AVAILABILITY STATEMENT Approved for public release; distribution is unlimited					
13. SUPPLEMENTARY NOTES N/A					
14. ABSTRACT <u>1. Contingency Preparedness:</u> Collect information from transplant centers, build awareness of the Transplant Center Contingency Planning Committee and educate the transplant community about the critical importance of establishing a nationwide contingency response plan. <u>2. Rapid Identification of Matched Donors :</u> Increase operational efficiencies that accelerate the search process and increase patient access are key to preparedness in a contingency event. <u>3. Immunogenetic Studies:</u> Increase understanding of the immunologic factors important in HSC transplantation. <u>4. Clinical Research in Transplantation:</u> Create a platform that facilitates multicenter collaboration and data management.					
15. SUBJECT TERMS Research in HLA Typing, Hematopoietic Stem Cell Transplantation and Clinical Studies to Improve Outcomes					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Same as Report	18. NUMBER OF PAGES 22	19a. NAME OF RESPONSIBLE PERSON Dennis L. Confer, MD – Chief Medical Office
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (Include area code) 612.362.3425

Grant Award N00014-08-1-1207

QUARTERLY
PERFORMANCE / TECHNICAL REPORT
FOR
JULY 01, 2009 to SEPTEMBER 30, 2009
PERIOD 4

Office of Naval Research

And

The National Marrow Donor Program
3001 Broadway Street N.E.
Minneapolis, MN 55413
1-800-526-7809

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

TABLE OF CONTENTS			
TASK	DESCRIPTION	STATUS	PAGE
IIA	Contingency Preparedness		
IIA.1	Objective 1 – Care Plans by Transplant Physicians		
IIA.1.1	Task 1 – Secure Interest of Transplant Physicians	Open	4
IIA.1.2	Task 2 – GCSF in Radiation Exposure	No Activity	4
IIA.1.3	Task 3 – Patient Assessment Guidelines	Open	4
IIA.1.4	Task 4 – National Data Collection and Management Model	Open	5
IIA.2	Objective 2 – Coordination of Care of Casualties		
IIA.2.1	Task 1 – Contingency Response Network	Open	6
IIA.2.2	Task 2 – Standard Operating Procedures	Open	6
IIA.3	Objective 3 – Information Technology Infrastructure		
IIA.3.1	Task 1 – Disaster Recovery	Open	7
IIA.3.2	Task 2 – Critical Facility and Staff Related Functions	Open	7
II.B	Rapid Identification of Matched Donors		
II.B.1	Objective 1 – Resolution of Speeds Donor Selection		
IIB.1.1	Task 1 – Increase Registry Diversity	Open	8
IIB.1.2	Task 2 – Evaluate HLA-DRB1 High Resolution Typing	Closed	8
IIB.1.3	Task 3 – Evaluate HLA-C Typing of Donors	Closed	9
IIB.1.4	Task 4 – Evaluate Buccal Swabs	No Activity	9
IIB.1.5	Task 5 – Enhancing HLA Data for Selected Donors	Open	9
IIB.1.6	Task 6 – Maintain a Quality Control Program	Open	10
IIB.2	Objective 2 – Improve HLA Quality & Resolution		
IIB.2.1	Task 1 – Collection of Primary Data	No Activity	11
IIB.2.2	Task 2 – Validation of Logic of Primary Data	Closed	11
IIB.2.3	Task 3 – Reinterpretation of Primary Data	Closed	11
IIB.2.4	Task 4 – Genotype Lists & Matching Algorithm	Open	11
IIB.3	Objective 3 – Algorithm to Predict Best Donor		
IIB.3.1	Task 1 – Incorporate Frequencies into Matching Algorithm	Open	11
IIB.3.2	Task 2 – Enhancement of EM Algorithm	Open	12
IIB.3.3	Task 3 – Optimal Registry Size Analysis	Open	12
IIB.3.4	Task 4 – Target Underrepresented Phenotypes	Open	12
IIB.3.5	Task 5 – Bioinformatics Web Site	Closed	12

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

IIB.3.6	Task 6 – Utilize Search Strategy Advisors to Improve Algorithm	Closed	12
IIB.3.7	Task 7 – Population Genetics	Open	13
IIB.3.8	Task 8 – Haplotype Matching	No Activity	13
IIB.3.9	Task 9 – Global Haplotype/Benchmark	No Activity	13
IIB.4	Objective 4 – Reduction of Donor Matching Time		
IIB.4.1	Task 1 – Expand Network Communications	No Activity	13
IIB.4.2	Task 2 – Central Contingency Management	Open	13
IIB.4.3	Task 3 – Benchmarking Analysis	Closed	13
IIB.4.4	Task 4 – Expand Capabilities of Collection and Apheresis Centers	Closed	14
IIC.	Immunogenetic Studies		
IIC.1	Objective 1 – Influence of HLA Mismatches		
IIC.1.1	Task 1 – Donor Recipient Pair Project	Open	14
IIC.2	Objective 1 – Role of Other Loci and GVHD		
IIC.2.1	Task 1 – Analysis of Non-HLA Loci	Open	15
IIC.2.2	Task 2 – Related Pairs Research Repository	No Activity	16
IIC.2.3	Task 3 – CIBMTR Integration	No Activity	16
IID	Clinical Research in Transplantation		
IID.1	Objective 1 – Clinical Research Improves Outcomes		
IID.1.1	Task 1 – Observational Research, Clinical Trials and NIH Transplant Center	Open	16
IID.1.2	Task 2 – Research with NMDP Donors	Open	18
IID.1.3	Task 3 – Expand Immunobiology Research	Open	18
	Acronym List		20

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

IIA. Contingency Preparedness – Objective 1: Recovery of casualties with significant myelosuppression following radiation or chemical exposure is optimal when care plans are designed and implemented by transplant physicians

IIA.1.1 Task 1: Secure Interest of Transplant Physicians	Period 4 Activity: During 2009 a total of 320 RITN center staff successfully completed the Basic Radiation Training (BRT); since its' creation in 2006 1,969 RITN center staff have successfully completed BRT; this is a passing rate of 96.5%.
IIA.1.2 Task 2: GCSF in Radiation Exposure	Period 4 Activity: No activity this period.
IIA.1.3 Task 3: Patient Assessment Guidelines and System Enhancements	Period 4 Activity: Contingency: - Participated in the Donor Contingency Portal projects periodic status meetings and project definition. STAR Link Web and Do It Yourself (DIY) application efforts were focused on development of features and enhancements for the Navy Contingency project. This project provides the ability to electronically contact selected donors via email and allow them to complete an online Health History Questionnaire (HHQ) from the DIY platform. Work efforts were focused on the following areas, with a production release date of 10/15/09: - Health History Questionnaire (HHQ) – Enhancements: - Void form enhancement - DIY HHQ Form FDA required Language changes - Online Donor HHQ references added to Search Folder HHQ Summary Screen Setup - Checkbox “Show Detail Status” on Pending Search screen - Initiation of Online HHQ - Review of Online HHQ verification - Report that displays original responses from donor that have completed an Online HHQ

QUARTER PROGRESS REPORT**Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2009 through September 30, 2009**

	In the next quarter, pilot testing, metrics capture and analysis will continue with this effort. Other efforts for the Contingency Project include: - Completed the following project initiation and analysis deliverables to support future releases on the Navy Contingency Project: - Draft Quality Assurance Plan - Draft requirements/use case for iteration 3 (Voids) - Iteration 4 requirements/use case (Accurint) - Define/Tag Affected donor requirements/use case - DIY extension requirements/use case - Communicate to donors requirements/use case - Began documenting requirements for manage affected donor requirements/use case - Statistic: DIY Online Donor Registration through www.marrow.org resulted in a total of 75,077 between 1/1/08 – 9/30/09. Data Warehouse/Data Mart Reporting: - In the last quarter the Do It Yourself Recruitment (DIY) Data Mart was deployed to production. This Data Mart will provide the foundation for the Navy Contingency reporting of donor contingency response.
IIA 1.4 Task 4: National Data Collection Model	Period 4 Activity: No activity this period.

QUARTER PROGRESS REPORT**Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2009 through September 30, 2009**

IIA. Contingency Preparedness – Objective 2: Coordination of the care of casualties who will require hematopoietic support will be essential in a contingency situation.

IIA.2.1 Task 1:
Contingency
Response Network

Period 4 Activity:

- Supported completion of RITN tasks by participating centers and coordinated the distribution of grant payments to centers once their tasks were satisfactorily completed all tasks.
 - 90% of RITN centers completed their FY09 tasks; five centers were offered extensions to complete their tasks before the end of calendar year 2009.
 - Currently there are a total of 57 RITN centers; two were inactive and four new centers joined the network during FY09.
- Conducted three Monthly RITN Conference Calls for center contacts to discuss issues related to the completion of tasks at their centers with the intent of sharing best practices between centers.
- Created and distributed three “Radiation In the News” radiation event summary reports for distribution to RITN center staff to keep them abreast of radiological related incidents occurring around the globe.
- Attended the Oklahoma University Medical Center Tabletop exercise

IIA.2.2 Task 2:
Sibling Typing
Standard Operating
Procedures

Period 4 Activity:

- Discussed options with Dr. Confer on how best to accomplish this task with minimal IT systems changes

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

IIA. Contingency Preparedness – Objective 3: NMDP's critical information technology infrastructure must remain operational during contingency situations that directly affect the Coordinating Center.

IIA.3.1 Task 1:

I.S. Disaster
Recovery

Period 4 Activity:

- Conducted a Business Continuity Exercise with Search & Transplant and Donor Resources departments in September 2009. Key staff was able to access the NMDP production Data Center in Minnetonka from a remote staff recovery site and was able to work through their critical task lists.
- Additional hardware was purchased, installed and configured to support Disaster Recovery environment and Business Continuity Exercise. Additional network devices were also set up and configured to support the Disaster Recovery environment and to support Business Continuity tests.

IIA.3.2 Task 2:

Critical Facility and
Staff Related
Functions

Period 4 Activity:

- **Business Continuity Planning:**
 - Completed the development of the organization Business Continuity Plan and acquired Chief Executive Officer approval for final publication and implementation of the plan.
 - Conducted the organization's first business continuity exercise (BCPeX-2009):
 - 20 staff from Donor Resources and the Search Coordinating Unit conducted critical tasks from a remote non-NMDP location (nearby Ramada hotel).
 - Staff connected to the new Unified Communications system demonstrating that the new Internet based telecommunications system is able to connect staff at any location with the appropriate level of Internet access and necessary equipment.
 - Completed the first comprehensive review of the critical task and staff list by the Critical Task List Review Committee.
 - Pandemic influenza preparedness was accomplished:
 - Developed influenza specific HR policies and organizational response plans to be implemented once an NMDP emergency is declared.
 - Informed staff of the developing influenza pandemic situation.
 - Created and conducted training on reducing the spread of influenza in the workplace to 82% of NMDP staff (still ongoing).

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

IIB. Rapid Identification of Matched Donors – Objective 1: Increasing the resolution and quality of the HLA testing of volunteers on the registry will speed donor selection.

IIB.1.1 Task 1: Increase Registry Diversity	Period 4 Activity: Five contracted laboratories performed HLA-A, B, DRB1 typing and one laboratory performed HLA-A, B, C, DRB1 typing, on 82,268 newly recruited donors funded by this grant. • Blind quality control testing error rate was 0.03%, meeting the project requirement of $\leq 2.0\%$. • On-time testing completion rate was 98 %, meeting the project requirement of a minimum of 90% of typing results reported within 14 days of shipment of samples. <u>Adult Donor Registry:</u> • To successfully serve all patients in need of cellular transplantation, the Marketing and Communications Department continues to focus on developing and executing strategies and tactics that increase awareness, education and engagement among target audiences. During the July – September 2009 time-frame, we developed marketing materials and tools to support the launch of the “Say it Loud...Save Lives and Be Proud” program. This program is a comprehensive approach to engaging Historically Black College and University (HBCU) students and their community in our mission to save lives. A key component of this program is the launch of a Be The MatchSM Web site on the HBCU Connect online platform. This platform is the premiere online channel for HBCU students and alumni. The site will serve as a key tool to help educate this community about the need for more African Americans to join the registry and to donate marrow when called. It will also feature stories about HBCU schools that are hosting drive events on campus and stories about committed donors and the lives they have saved. Additionally, Marketing and Communications strengthened its outreach to the Hispanic/Latino community by developing key additional educational materials in the Spanish language to enhance this community’s drive-related experience and their participation in our mission.
IIB.1.2 Task 2: Evaluate HLA-DRB1 High Res typing	Period 4 Activity: • This activity is closed.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

IIB.1.3 Task 3: Evaluate HLA-C Typing of Donors	Period 4 Activity: This activity is closed.
IIB.1.4 Task 4: Evaluate Buccal Swabs	Period 4 Activity: Sample Storage Research Study (SSRS) 30 donor samples (frozen blood, blood spotted onto filter paper, and 2 buccal swabs for each donor) were sent to two laboratories for the 2 year time point of the study in September, 2009. Preliminary review of the data shows 100% accuracy in HLA typing, and good quality and quantity of DNA for all samples. 8 samples needed repeat testing at one locus: 2 blood samples, 1 filter paper sample, and 5 buccal swabs. This resulted in a 1.7% repeat rate. All repeat testing was 100% accurate.
IIB 1.5 Task 5: Enhancing HLA Data for Selected Donors	Period 4 Activity: This aim consists of registry-based typing projects, which have the potential to strategically identify and improve the HLA typing and availability of donors most likely to match searching patients from domestic TCs. All strategies being evaluated are extensions of the previous Replacement Donor and Optimal Donor typing projects. - Back-Up Donor Project: While the primary study was completed in December 2007, the NMDP staff has continued to monitor the patient-directed utilization of the 206 donors prospectively typed in this project. To date we have observed the activation of 16 donors for CT requests, followed by 6 workup requests and 3 subsequent stem cell donations. An abstract reporting the results of this study was accepted for a poster presentation at the 2009 ASHI annual meeting. - Optimal Donor Project: While the project was officially completed in 2008, NMDP staff has continued to monitor the patient-directed utilization of the 462 donors prospectively typed in this project. Current follow-up of these donors revealed the activation of 20 donors for CT requests, followed by 2 hold-for-workup requests, 2 workup requests and 1 stem cell donation. An abstract reporting the results of this study was accepted for oral presentation at the 2009 ASHI annual meeting. - Preliminary Search / Donor Contact project (minority donor sub-group): prospective typing of 422 minority donors was completed in late October 2008. Current follow-up of these donors revealed

QUARTER PROGRESS REPORT**Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2009 through September 30, 2009**

	the activation of 2 donors for CT requests. • Evaluation of HLA-AB only typed donors potentially matching patients with formal searches: Patient searches with active work-up requests were evaluated and searches identified for which there are relatively few 6/6 matched donors. 691 donors were selected from the HLA-AB only typed pool and tested for HLA-DRB1. Prospective typing was completed in March 2009. Current follow-up of these donors revealed the activation of 7 donors for CT requests on behalf of different patients, 2 workup requests and 1 stem cell donation. • Continuing analysis of patients associated with Optimal Donor project that had zero potential 6/6 donor matches in NMDP hosted registry or BMDW. As previously reported, 4,931 donors were identified who potentially matched the study patients. 1,359 donors with repository samples were selected for prospective typing. AB only donors selected were associated with unique phenotypes not seen in the fully typed donor population or phenotypes with few (2-10) donors. Current follow-up of these donors revealed the activation of 10 donors for CT requests on behalf of 9 different patients, followed by a stem cell donation for a patient who had searched for almost two years. These donors had been on the registry from 8-14.7 years prior to prospective typing, but were then activated for new patients within an average of 228 days. An abstract reporting the results of this study was accepted for poster presentation at the 2009 Annual ASHI meeting. • Performed an additional 460 donor selections for prospective HLA typing using our Optimal Donor selection strategies now for patient phenotype categories with only 1-2 potentially allele-matching donors. Current follow-up of these donors revealed the activation of 5 donors for CT requests on behalf of 5 different patients, within an average of 86 days of the availability of upgrade HLA typing results.
IIB 1.6 Task 6: Maintain a Quality Control Program	Period 4 Activity: • 121 new unique B-LCLs were added to the QC Master inventory. 19 of these cell lines were selected due to rare alleles contained in their haplotypes. Blind QC Swab samples will be created from these cell lines for shipment as needed.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

IIB. Rapid Identification of Matched Donors – Objective 2: Primary DNA typing data can be used within the registry to improve the quality and resolution of volunteer donor HLA assignments.

IIB 2.1 Task 1: Collection of Primary Data	Period 4 Activity: No activity this period.
IIB 2.2 Task 2: Validation of Logic of Primary Data	Period 4 Activity: This activity is closed.
IIB 2.3 Task 3: Reinterpretation of Primary Data	Period 4 Activity: This activity is closed.
IIB 2.4 Task 4: Genotype Lists & Matching Algorithm	Period 4 Activity: - Conducted re-interpretation of approximately 270,000 probe results to the HLADB 2.4.0 allele list in production. - Wrote program to “validate and push” probe results making them available to systems using HapLogic. Donors in the registry prior to February, 2007 had already been pushed and have been used for searches; with this quarter's effort primary data from donors stored since 2007 are starting to be used in searches.

IIB. Rapid Identification of Matched Donors – Objective 3: Registry data on HLA allele and haplotype frequencies and on the nuances of HLA typing can be used to design computer algorithms to predict the best matched donor.

IIB.3.1 Task 1: Phase I of EM Haplotype Logic	Period 4 Activity: - Approach for HapLogic III presented to the NMDP Histocompatibility Advisory Group on July 9, 2009. Feedback was very helpful to determine scope of work for HapLogic III. - Project Charter and technical documentation created to outline work planned to be done. - Prototype for HapLogic Phase III added ARS logic. Internal validation testing continued in order to test the HapLogic III prototype (which includes x of 10 matching and sorting, x of 8 matching and sorting, and a single value “allele” sort based on a weighted average matching score).
---	--

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

IIB 3.2 Task 2: Enhancement of EM Algorithm	Period 4 Activity: - Based on genetic distance, the size of the donor cohorts, and data integrity, the 147 detailed race and ethnic categories were combined and pruned to 21 operationally useful categories which will be used for HapLogic III and registry modeling. - High-resolution haplotype frequencies were generated using all DNA-typed donors in the 21 population categories for the A-B-DRB1, C-B, DRB1-DQB1, A-C-B-DRB1, and A-C-B-DRB1-DQB1 loci.
IIB 3.3 Task 3: Optimal Registry Size Analysis	Period 4 Activity: A preliminary report was issued on September 30th listing the current probabilities of 8/8 and 7/8 match at A,C,B,DRB1 for adult donors and 4/6, 5/6, and 6/6 match at A,B, and DRB1 using criteria for cord blood matching in the 21 population categories. The final report with registry growth scenarios and analysis details will be released next quarter.
IIB 3.4 Task 4: Target Under-Represented Phenotypes	Period 4 Activity: - Feedback was received on prototype using ESRI-ARC GIS Geographical Analysis software regarding better data representation, finding representative frequencies in low population areas, geospatial correlation of 2 variables tools, and how to evaluate data integrity in outliers. In the next quarter planning to update prototype to incorporate that feedback. - Updated agreement for NCOA information sent from ZDI to include latitude/longitude information for use in this project.
IIB 3.5 Task 5: Bioinformatics Web Site	Period 4 Activity: This activity is closed.
IIB 3.6 Task 6: Consultants to Improve Algorithm	Period 4 Activity: This activity is closed.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

IIB 3.7 Task 7: Population Genetics	Period 4 Activity: During the past quarter we worked on building relationships with external collaborators for the development of enhancements to the registry matching models.
IIB 3.8 Task 8: Haplotype Matching	Period 4 Activity: No activity this period.
IIB 3.9 Task 9: Global Haplotype/Benchmark	Period 4 Activity: No activity this period.
IIB. Rapid Identification of Matched Donors – Objective 4: Reducing the time and effort required to identify closely matched donors for patients in urgent need of HSC transplants will improve access to transplantation and patient survival in the context of a contingency response and routine patient care.	
IIB.4.1 Task 1: Expand Network Communications	Period 4 Activity: No activity this period.
IIB.4.2 Task 2: Central Contingency Management	Period 4 Activity: Donor testing continued for the research project to validate the “actual” 8/8 HLA high resolution match rate for both CAU and AFA patients and supply valuable information regarding donor selection in the event of a contingency. Donors are being tested in rounds of priority for cost efficiency. During this period, three rounds of donor testing were performed (N=1162 loci total) and results compiled for the analysis. Additional testing rounds will continue next quarter to complete the testing required for the analysis.
IIB.4.3 Task 2: Benchmarking Analysis	Period 4 Activity: This activity is closed.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

IIB.4.4 Task 2: Expand Capabilities of Collection and Apheresis Centers	Period 4 Activity: This activity is closed
IIC. Immunogenetic Studies – Objective 1: HLA mismatches may differ in their impact on transplant outcome, therefore, it is important to identify and quantify the influence of specific HLA mismatches. In contingency situations it will not be possible to delay transplant until a perfectly matched donor can be found.	
IIC.1.1 Task 1: Donor Recipient Pair Project	Period 7 Activity: In 1994 a retrospective D/R Pair HLA typing project to characterize class I and class II alleles of donor/recipient paired samples from NMDP's Repository was initiated. The goals of this ongoing research project are to assay the impact of DNA-based HLA matching on unrelated donor transplant outcome, develop strategies for optimal HLA matching, evaluate the impact of matching at alternative HLA loci on transplant outcome and finally to promote the development of DNA-based high resolution HLA typing methodologies. - All outstanding typing issues from prior SGs were compiled and assigned to a Tie-Breaker laboratory. Full analysis and audit will be completed early next quarter. 273 pairs of sample Group 22 whose period of performance came to a close on April 30, 2009 have been audited and are available for inclusion in research studies. - The project period for SG23 came to a close on August 31, 2009. The contracts for SG23 (400 pairs) testing include intermediate and high resolution HLA. No-Make resolution and discrepancy analyses have been initiated. Audit of the 400 pairs will occur next quarter. - Sample Group 24 (400pairs) was initiated on August 31, 2009. Inclusion of high resolution DPB1 typing on all samples occurred within SG 24. The period of performance is from August 31, 2009 to December 31, 2009. Current HLA matching guidelines for unrelated HCT recommend avoidance of mismatches only within the ARS. This recommendation is based on the hypothesis that amino acid differences outside the ARS are not immunogenic. The ARS allo-reactivity assessment project will give insight into the allowable percent tolerance of matching needed outside of the ARS.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

- Initiated investigation of the first class II non-ARS mismatch (DRB1*140101/1454) where both alleles have been seen in the same genotype. Specific queries of the Be The Match Registry allowed for selection of ninety-nine potential donors to be typed at high resolution.
- HLA-A, B, C, DRB1/3/4/5, DQA/B1 and DPB1 typings were completed on all 99 donors. Selection of potential study participants is ongoing.

IIC. Immunogenetic Studies – Objective 2: Even when patient and donor are HLA matched, GVHD occurs so other loci may play a role.

IIC 2.1 Task 1:
Analysis of non-
HLA loci

Period 4 Activity:

The Immunobiology Project Results (IPR) database and its applications will allow for storage and analysis of all immunogenetic data collected on NMDP research samples. This database will replace the existing HLA donor/recipient pair's database and facilitate storage and analysis of data from other immunogenetic loci (KIR, microsatellites, single nucleotide polymorphisms, etc).

- The Scientific Services and Bioinformatics departments continued to collaborate on the design and development of the IPR database application and tools.
- Quality assurance progressed on the application that accepts, validates, and stores incoming HLA and KIR typing data via HML.
- Development was initiated for reports that support the business user's ability to track typing requests and their results.
- Development was completed for an application which loads transplant center typings.
- Development was completed for an application that compares typings between the labs and the transplant centers.
- Requirements and specifications were completed for software tools that monitor and resolve typing discrepancies.
- Requirements were 100% completed and specifications 80% completed for tools that allow the business user to monitor, alter, and audit data.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

	Requirements and specifications were initiated for software that automates the processing flow of the data from loading to data analysis to comparison between the labs to auditing to selection for study.
IIC 2.2 Task 2: Related Pairs Research Repository	Period 4 Activity: No activity this period.
IIC 2.3 Task 3: CIBMTR Integration	Period 4 Activity: No activity this period.
IID. Clinical Research in Transplantation – Objective 1: Clinical research in transplantation improves transplant outcomes and supports preparedness for a contingency response.	
IID.1.1 Task 1: Observational Research, Clinical Trials and NIH Transplant Center	Period 4 Activity: AGNIS Activity: - Completed development and internal quality assurance for AGNIS 2.0 to publish functionality supporting Forms 2400, 2450 and 2900 - Provided support for external testing and development using AGNIS 2.0 Publish functionality - Completed development and internal QA for AGNIS 2.0 form Submission for Form 2900, functionality released to external development site for use by transplant centers - Completed development for AGNIS 2.0 form Submission for Forms 2400 and 2450. - Completed development and QA of a Meta Data Tool to assist transplant center data mapping to caDSR curated forms, released with supporting documentation via AGNIS.net website. - Completed requirements for the AGNIS Enhanced Staging Client, this tool will support transplant center submission and retrieval of forms through AGNIS, requirements have been review with transplant centers on the weekly AGNIS conference call - Successfully hosted an IT Summit at NMDP attended by over 110 transplant center data management and IT staff, which included various presentations on AGNIS and data management related topics

QUARTER PROGRESS REPORT**Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2009 through September 30, 2009****FormsNet Activity:**

- FormsNet v2.9 (Donor Forms and Functionality). Delivered as planned on August 6, 2009.
- Development and Quality Testing continues for FormsNet v2.10 (26 Recipient Forms updates/modifications). Planned delivery is November 23rd, 2009.
- Development and Quality Testing continues for FormsNet v2.11 (Clinical Trials module and 17 RDSafe Forms). Planned delivery is November 23rd, 2009.
- Analysis has begun for FormsNet v3.0 with major upgrades to Web-interface and underlying web services. Planned delivery is late winter 2010.

Observational Research

- Staff continued work on various observational studies within the area of Immunobiology and GVHD and Graft Sources Working Committees.
- A total of 20 abstracts were submitted to the 2009 ASH meetings during this reporting period from all the CIBMTR Working Committees of which one was from a committee supported by this grant.

Prospective Studies; RCI BMT

- During this report period, accrual to the BMT CTN PBSC vs. Marrow trial was completed. Follow up activities will continue for two years on the patients and three years on the donors.
- Adult Double Cord trial activity during this period included four patients being enrolled for a total of 21 patients accrued to this study, giving us a 38% completion rate. Staff continues to coordinate and complete monthly PI and coordinator calls, manage data collection and monitor sites. During this report period staff updated a variety of coordinator and site materials.
- Revlimid trial activity continued during this period. Sites have enrolled patients onto this study using the EMMES developed data capture forms. Minor revisions have been identified and have or are currently being revised.

Note: The sentence related to staff time for the 07-Revlimid trial included in the last Quarterly Report for Period 3 and submitted in August 2009 was included in error.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

IID.1.2 Task 2: Research with NMDP Donors	Period 4 Activity: • Staff continued support of a Donor Ethnicity study with Dr. Galen Switzer from the University of Pittsburgh. • Staff continued to collaborate on a COG KIR study. Activities include facilitating the collection of a donor blood sample and shipment to the study lab. To date, 24 patients have been enrolled and 83 donor samples requested. • The protocol for long-term donor follow-up, consisting of revised questions, was finalized. The protocol is on track to complete the approval process in fall 2009. Work was begun on identifying and streamlining the operational processes needed to implement this protocol and proceed with centralization of the follow-up. • During this review period staff was involved in optimizing processes to support research studies that include donor samples.
IID.1.3 Task 3: Expand Immuno- biology Research	Period 7 Activity: The CIBMTR IBWC met monthly during the quarter to discuss progress on ongoing research studies • The scientific director and Ph.D. statisticians attended and participated in the CIBMTR External Scientific Agenda review. • Five manuscripts were submitted for publication: ○ David Valcarcel, et al. <i>One Antigen Mismatched Related vs. HLA-Matched Unrelated Donor Hematopoietic Transplantation in Adults with Acute Leukemia: CIBMTR Results in the Era of Molecular Typing</i>. Submitted to Blood. ○ Stephen Spellman, et al. <i>The Detection of Donor-Directed, HLA-Specific Alloantibodies in Recipients of Unrelated Hematopoietic Cell Transplantation is Predictive of Graft Failure</i>. Submitted to Blood. ○ Susana Marino, et al. <i>Mismatched Unrelated Donor Stem Cell Transplantation: Identification of HLA Class I Amino Acid Substitutions Associated with Survival at Day 100</i>. Submitted to Blood. ○ David McDermott, et al. <i>Donor and Recipient Chemokine Receptor CCR5 Genotype is Associated with Survival after Bone Marrow Transplantation</i>. Submitted to Blood.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

- o Yume Nguyen, et al. *Insufficient Evidence for Association of NOD2/CARD15 or Other Inflammatory Bowel Disease-Associated Markers on GVHD Incidence or Other Adverse Outcomes in T-Replete, Unrelated Donor Transplantation*. Submitted to Blood.
- Two abstracts were submitted and accepted for presentation at the 2009 American Society of Hematology annual meeting:
 - o Yasuo Morishima, et al. *Impact of Donor-Recipient Ethnicity on Risk of Acute Graft-Versus-Host Disease, Leukemia Relapse and Survival in Hematopoietic Stem Cell Transplantation from HLA-Compatible Unrelated Donors. A Report from the International Histocompatibility Workshop Group*. Accepted for oral presentation.
 - o Sarah Cooley, et al. *Choosing Donors with Favorable KIR B Genotypes for Unrelated Hematopoietic Transplantation Results in Superior Relapse Protection and Better Relapse-Free Survival for Patients with AML*. Accepted for oral presentation.

Funding for CIBMTR IBWC studies:

- Research funds were awarded to support DNA extraction and preparation of 408 samples for a study evaluating genome wide genetic diversity and the impact on acute graft versus host disease. The extractions will be completed early next quarter.

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

ACRONYM LIST

AABB	American Association of Blood Banks	ICRHER	International Consortium for Research on Health Effects of Radiation
AGNIS	A Growable Network Information System	IS	Information Services
AML	Acute Myelogenous Leukemia	IT	Information Technology
ARS	Acute Radiation Syndrome (also known as Acute Radiation Sickness)	IRB	Institutional Review Board
ASBMT	American Society for Blood and Marrow Transplantation	JCAHO	Joint Commission on Accreditation of Healthcare Organizations
ASHI	American Society for Histocompatibility and Immunogenetics	KIR	Killer Immunoglobulin-like Receptor
B-LCLs	B-Lymphoblastoid Cell Lines	NCI	National Cancer Institute
BARDA	Biomedical Advanced Research and Development Authority	MHC	Major Histocompatibility Complex
BMT CTN	Blood and Marrow Transplant - Clinical Trials Network	MICA	MHC Class I-Like Molecule, Chain A
BRT	Basic Radiation Training	MICB	MHC Class I-Like Molecule, Chain B
C&A	Certification and Accreditation	MDACC	MD Anderson Cancer Center
CBMTG	Canadian Blood and Marrow Transplant Group	MSKCC	Memorial Sloan-Kettering Cancer Center
CBB	Cord Blood Bank	MUD	Matched Unrelated Donor
CBC	Congressional Black Caucus	NEMO	
CBS	Canadian Blood Service	NCBM	National Conference of Black Mayors
CBU	Cord Blood Unit	NHLBI	National Heart Lung and Blood Institute
CHTC	Certified Hematopoietic Transplant Coordinator	NIH	National Institutes of Health
CIBMTR	Center for International Blood & Marrow Transplant Research	NIMS	National Incident Management System
CLIA	Clinical Laboratory Improvement Amendment	NK	Natural Killer
CME	Continuing Medical Education	NMDP	National Marrow Donor Program
CMF	Community Matching Funds	NRP	National Response Plan
COG	Children's Oncology Group	NST	Non-myeloablative Allogeneic Stem Cell Transplantation

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

July 01, 2009 through September 30, 2009

CREG	Cross Reactive Groups	OCR/ICR	Optical Character Recognition/Intelligent Character Recognition
CSS	Center Support Services	OIT	Office of Information Technology
CT	Confirmatory Testing	OMB	Office of Management and Budget
CTA	Clinical Trial Application	ONR	Office of Naval Research
DC	Donor Center	P2P	Peer-to-Peer
DIY	Do it yourself	PBMC	Peripheral Blood Mononuclear Cells
DKMS	Deutsche Knochenmarkspenderdatei	PBSC	Peripheral Blood Stem Cell
DMSO	Dimethylsulphoxide	PCR	Polymerase Chain Reaction
DNA	Deoxyribonucleic Acid	PSA	Public Service Announcement
D/R	Donor/Recipient	QC	Quality control
EBMT	European Group for Blood and Marrow Transplantation	RCC	Renal Cell Carcinoma
EM	Expectation Maximization	RCI BMT	Resource for Clinical Investigations in Blood and Marrow Transplantation
EMDIS	European Marrow Donor Information System	REAC/TS	Radiation Emergency Assistance Center/Training Site
ERSI	Environment Remote Sensing Institute	RFP	Request for Proposal
FBI	Federal Bureau of Investigation	RFQ	Request for Quotation
FDA	Food and Drug Administration	RG	Recruitment Group
FDR	Fund Drive Request	RITN	Radiation Injury Treatment Network
Fst	Fixation Index	SBT	Sequence Based Typing
GETS	Government Emergency Telecommunications Service	SCTOD	Stem Cell Therapeutics Outcome Database
GCSF	Granulocyte-Colony Stimulating Factor (also known as filgrastim)	SG	Sample Group
GIS	Geographic Information System	SLW	STAR Link® Web
GvHD	Graft vs Host Disease	SSA	Search Strategy Advice
HCT	Hematopoietic Cell Transplantation	SSO	Sequence Specific Oligonucleotides
HHS	Health and Human Services	SSP	Sequence Specific Primers
HIPAA	Health Insurance Portability and Accountability Act	SSOP	Sequence Specific Oligonucleotide Probes

QUARTER PROGRESS REPORT**Development of Medical Technology for Contingency Response to Marrow Toxic Agents****July 01, 2009 through September 30, 2009**

HLA	Human Leukocyte Antigen	STAR®	Search, Tracking and Registry
HML	Histoimmunogenetics Mark-up Language	TC	Transplant Center
HR	High Resolution	TED	Transplant Essential Data
HRSA	Health Resources and Services Administration	TNC	Total Nucleated Cell
HSC	Hematopoietic Stem Cell	TSA	Transportation Security Agency
IBWC	Immunobiology Working Committee	UI	User Interface
IDM	Infectious Disease Markers	URD	Unrelated Donor
IHWG	International Histocompatibility Working Group	WGA	Whole Genome Amplification
IPR	Immunobiology Project Results	WMDA	World Marrow Donor Association
IND	Investigational New Drug	WU	Work-up